

# Abraham Al-Mamgani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115121/publications.pdf>

Version: 2024-02-01

44  
papers

2,046  
citations

293460

24  
h-index

274796

44  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2853  
citing authors

#	ARTICLE	IF	CITATIONS
1	The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6Âmm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction. <i>Radiotherapy and Oncology</i> , 2022, 168, 16-22.	0.3	12
2	Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile. <i>Oral Oncology</i> , 2022, 127, 105782.	0.8	7
3	Deterioration of Intended Target Volume Radiation Dose Due to Anatomical Changes in Patients with Head-and-Neck Cancer. <i>Cancers</i> , 2021, 13, 4253.	1.7	2
4	Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes. <i>Radiotherapy and Oncology</i> , 2021, 162, 170-177.	0.3	10
5	Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 261-268.	0.8	11
6	Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. <i>Radiotherapy and Oncology</i> , 2020, 142, 79-84.	0.3	37
7	Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 960-968.	0.4	14
8	Prostate-specific membrane antigen positron emission tomography/computed tomography as a potential tool to assess and guide salivary gland irradiation. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 9, 65-68.	1.2	7
9	Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 288-296.	1.1	4
10	The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirusâ€“Positive Versus Human Papillomavirusâ€“Negative Patients With Oropharyngeal Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e323-e328.	0.7	13
11	Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 1023-1033.	1.1	23
12	Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status. <i>Oral Oncology</i> , 2018, 78, 200-206.	0.8	15
13	Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2018, 125, 478-486.	0.2	58
14	Local control in sinonasal malignant melanoma: Comparing conventional to hypofractionated radiotherapy. <i>Head and Neck</i> , 2018, 40, 86-93.	0.9	6
15	Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation. <i>Radiotherapy and Oncology</i> , 2018, 128, 472-478.	0.3	33
16	Unknown primary head and neck squamous cell carcinoma in the era of fluorodeoxyglucoseâ€“positron emission tomography/CT and intensityâ€“modulated radiotherapy. <i>Head and Neck</i> , 2017, 39, 1382-1391.	0.9	11
17	Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1691-1700.	0.8	10
18	The price of robustness; impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 120, 56-62.	0.3	49

#	ARTICLE	IF	CITATIONS
19	Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. International Journal of Radiation Oncology Biology Physics, 2015, 93, 337-343.	0.4	49
20	Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 190-195.	0.4	23
21	Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy. European Archives of Oto-Rhino-Laryngology, 2014, 271, 125-132.	0.8	45
22	Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology, 2014, 110, 104-109.	0.3	171
23	Fully Automated Volumetric Modulated Arc Therapy Plan Generation for Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1175-1179.	0.4	115
24	Adjunctive treatment of keloids: comparison of photodynamic therapy with brachytherapy. European Journal of Plastic Surgery, 2013, 36, 289-294.	0.3	5
25	Unilateral neck irradiation for well-lateralized oropharyngeal cancer. Radiotherapy and Oncology, 2013, 106, 69-73.	0.3	51
26	Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. European Archives of Oto-Rhino-Laryngology, 2013, 270, 293-299.	0.8	77
27	Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: Comparable outcomes of two different approaches. Oral Oncology, 2013, 49, 1018-1024.	0.8	17
28	Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial. Radiotherapy and Oncology, 2013, 107, 134-139.	0.3	24
29	Node-positive hypopharyngeal cancer treated by (chemo)radiotherapy: Impact of up-front neck dissection on outcome, toxicity, and quality of life. Head and Neck, 2013, 35, 1278-1286.	0.9	14
30	The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer. Laryngoscope, 2013, 123, 386-393.	1.1	66
31	IMRT for Image-Guided Single Vocal Cord Irradiation. International Journal of Radiation Oncology Biology Physics, 2012, 82, 989-997.	0.4	47
32	Stereotactic Body Radiotherapy: A Promising Treatment Option for the Boost of Oropharyngeal Cancers Not Suitable for Brachytherapy: A Single-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1494-1500.	0.4	26
33	A Single-Institutional Experience of 15 Years of Treating T3 Laryngeal Cancer With Primary Radiotherapy, With or Without Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1000-1006.	0.4	31
34	Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncology, 2012, 48, 905-911.	0.8	24
35	Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (Chemo)radiation: The impact of treatment modality and radiation technique. Laryngoscope, 2012, 122, 1789-1795.	1.1	36
36	Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: Long-term outcomes, QoL assessment and review of the literature. Oral Oncology, 2012, 48, 278-283.	0.8	36

#	ARTICLE	IF	CITATIONS
37	Single vocal cord irradiation: A competitive treatment strategy in early glottic cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 415-419.	0.3	32
38	Dose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1004-1012.	0.4	49
39	Relating Dose Outside the Prostate With Freedom From Failure in the Dutch Trial 68 Gy vs. 78 Gy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 131-138.	0.4	40
40	Controversies in the treatment of high-risk prostate cancer—what is the optimal combination of hormonal therapy and radiotherapy: a review of literature. <i>Prostate</i> , 2010, 70, 701-709.	1.2	14
41	Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. <i>Radiotherapy and Oncology</i> , 2010, 96, 13-18.	0.3	30
42	Role of Intensity-Modulated Radiotherapy in Reducing Toxicity in Dose Escalation for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 685-691.	0.4	192
43	Cardiac metastases. <i>International Journal of Clinical Oncology</i> , 2008, 13, 369-372.	1.0	137
44	Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 980-988.	0.4	373